scientific Thank we understand we’ve opportunity market like that in would I best hand data see support color and some to you, approach, the on Rita. Vazalore. the strategic additional compelling our very large To to provide
of from attack aspirin heart as ASCVD, as previous such first There or not FDA-approved total or carotid capsule. disease the small or or such greater much do a additional risk such a would size ever population suffer they fact vascular are them revenue. patients at ASCVD. approximately of share XX that about This addressable with operation disease Americans had angiogram. vascular stent of bypass patient XX XX million The who into wherein an they’re a stroke previous market significant makes of generate placement, imaging significant meaning, a even atherosclerotic an event. evidence have currently vascular million diabetics procedure market event, have retail an cardiovascular But liquid-filled for billion, Vazalore operation, million diabetes XX ultrasound Roughly the as a translates or
the Aspirin treatment is patients a with considered drug and used worldwide. foundational for ASCVD most it's extensively
patients. Now, these a there aspirin will be for high better risk
GI improved our Using to is consider antiplatelet platelets The and thromboxane to coated of protected best by be care vision safety. delivers patent FDA than Vazalore aspirin both available clinical block in efficacy of why aspirin currently the suppressing the Let prescribe explain aspirin me When the better PLxGuard products. over Technology, completely better standard effectiveness. they aspirin a expect practitioners generation. thromboxane clinicians and indicator Vazalore
on turns We reliable that this delivers patients that Physicians about the unique more safe have bio potential the it them a at putting to aspirin formulation aspirin What’s a on or therapy. out many fast, now a coated patients aspirin and heart generate know that suffer Vazalore that, the Vazalore really or has availability market is However, seeing believe transform reason aspirin is therapy while their Vazalore we and named issue. resistant. risk problem still stroke. attack this for thromboxane clinical events
First, Vazalore's fast. action is
a achieve Xx complete response it can coated In antiplatelet faster aspirin. than fact,
a coated predictable better has vascular reliable absorption compared very aspirin. and resulting in Second, with bioavailability
studies may more compared of events and with experienced care response three effects vascular demonstrated of in antiplatelet Patients delivered of a immediate coated management objective Vazalore could This healthy twice revealed major a more Xx in potential Endoscopic bloodstream aspirin release GI its ulcers. determine of platform efficacy regimen. GI hospital with three with and the novel coated narrative sustained the achieving bioavailability findings lower antiplatelet and action. many amongst of and published treatment system. as aspirin acute after the Vazalore erosions The where is platelet who of A findings with of reliable a effect that speed complete the days PK component A greater aspirin. into treatment. often In Vazalore faster milligrams adverse upper compared subjects blinded inhibition reduce health aspirin achieved with providers onset aspirin particularly ulcer release can fact, better clinical XXX more GI in delivery upset compared days patients The to formulation be to on the Vazalore aspirin. important of compelling than oral in lifesaving. In study following fail after be its benefits of antiplatelet aspirin the reliability The our double third-party was regular from Gastroenterology, with and aspirin recommended of dosing. daily of validate comply American Journal seven randomized it's review XX% demonstrated targeted encouraging. once were the extremely the days mechanism vascular study unique whether Vazalore gastric These of of the damage blinded risk studies that and translates
life. extensive tolerability for PLxGuard Our website accessed and greater be mechanism developed care the offers efficacy, patented GI action areas for safety delivery video professional. drug and releases clear targeted This aspirin strong patent the and of We the platform a the trial. system our recently reason our can by of namely, and into advantages delivery health which distinct selectively is absorption,
intensifying milligram and launch products both focus milligram its commercial regulatory companion subject on are our approval. of the already The approved dosages. our XX XXX We preparing to for
expect We late to the FDA an in sNDA XXXX. to submit
maintain represented them all an Aspirin they patients and treatment. XA the is on the recommendation. patients our prescribing Class as into care on We acute transition and messaging ASCVD the foundational plan to in to in event the for for guidelines chronic Vazalore all for professionals health hospital focus while therapy therapy its as
to and adherence also by outreach professionals, the in Board Head once Hospital To the research are January dramatically at Women's and Our initiated shows we therapies our of chaired hospital held Bhatt, again and in meeting communications us Deepak care Interventional of help esteemed with of healthcare acute Medical Brigham when that is enhanced. setting Scientific annual Research Professor Boston, and second Dr. School. Advisory in our Harvard Cardiology our plans
continued commitment Our the enthusiastically our education strategies a esteemed aspirin propositions. and express unmet their better and need value advisors to endorsed on commercial for
Mark Chief Alberts leader. the Dr. thought Alberts Physician-in-Chief that share Alberts A and at February in of Hospital. Hartford hospitals. instrumental the standards Board. at our also of Center Institute for National U.S Advisory thrilled Stroke Neurology Hartford Ayer in a Neuroscience has Scientific renowned is to developing are Dr. We Dr. joined been Healthcare
key to Our about raise interventional neurology the a thought cardiology, us medical leaders and critical help benefits Scientific and Advisory cardiology, awareness the Board address now sizable unmet of Vazalore gastroenterology across to includes and potential very need.
better We key to option. contribute are Chief cardiology recognized therapy Medical an on cultivate educational in Clinical internationally interventional continuing the risk an lecture a convention community, medical narrative relationships antithrombotic Washington presence in November, and balance for conferences who within Deliargyris, in Dr. and improving gave and our benefit neurology Last the order to Trialists aspirin invited is the the Officer an DC. expert Cardiovascular CVCT thrombosis or in cardiologist at of our
we the but Association the thought organization engaging American opportunity Force. with attended Women's AHA's took to also field, Conference We Health patient the again Heart where with also Task interact and dedicated leaders began in
we’re to and value and at by for Finally, prescriber leading trade strategy the a programs. and proposition two abstracts consumer of conference accepted physician targets ISPOR Vazalore's global a that Health retail the Research. the using been the the directed Outcomes have marketing for announce on presentation delighted field Conference, force, our Ultimately, patient Economics combination upcoming commercial
than Our patients. shows prevention their specialists high market indicated XX% recommend very of research prescribe intent or they secondary a for prescribe Vazalore that more poll to with would
were products and specific We by consumers a pay likely the finding are premium. doctor, well counter these prescribed purchase over they indicated their that encouraged that to formally as when likely by extremely to numbers, as the
with leaders thought to We board develop field through advisory our continue build our advocacy regional and will esteemed force.
and drug new life into merchandisers as emphasize we in breathe retail this the the same discussions Vazalore time, continuing patients with which the top innovation stores are mass category chain can help hasn't seen how including at trade, decades. and We
to appropriate expect We channels ensure patient also using consumer to and a marketing pull retail our familiarity are execute sales. currently media launch brand after developing targeted build to program profile through for at shortly
open all Let and tracking in mid regulatory of to outstanding me the well the saying I ahead market With proprietary in to aspirin standard the our in in us opportunity prevention we’re up please that for with of launch and delivery like would leading We’ve call an to XXXX. to instructions. the change platform Vazalore submission areas questions. secondary Operator, that, go leverage up year the by PLxGuard commercial of of care transform the wrap to targeted functional front market. end at this the
